News
Displaying 41–50 of 519
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Research NewsMerger will provide additional capital for gene therapy development.
-
MicroRNA Breakthroughs: Paving the Way for Vision Restoration
Research NewsResearchers funded by the Foundation Fighting Blindness are developing microRNA-based therapies for inherited retinal diseases, building on recent Nobel Prize-winning discoveries.
-
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
Research NewsResearchers hope the molecule will slow the vision and hearing loss associated with USH3.
-
Vision: A Memoir of Blindness and Justice — A New York Times Editor’s Pick
Foundation News“Tatel’s humility and tenacity shine. The result is a stirring reflection on an extraordinary life,” Publishers Weekly
-
Foundation News
Social media campaign to encourage personal story sharing to spread awareness about blinding diseases and empower involvement with the Foundation Fighting Blindness.
-
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
Research NewsKnown as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.
-
AAVantgarde Bio’s Dual-Vector USH1B Gene Therapy Moves into Phase 1/2 Clinical Trial
Research NewsThe trial is the first ever for a dual AAV gene therapy delivered to the retina.
-
Foundation News
Innovative Ways to Support Research for Treatments and Cures for Blinding Diseases
-
Research News
The Phase 3 trial is expected to begin in Q1 2025
